Mad Catz Announces New Community-Designed Arcade Controller
KOWLOON, Hong Kong--(BUSINESS WIRE)--Mad Catz Global Limited, a leading innovator in gaming hardware, is pleased to announce the N.E.K.O. all-button arcade controller. N.E.K.O. is the first Mad Catz arcade controller designed in collaboration with FGC pro gamers and our core fans in the Japanese fighting game community. Incorporating professional and community-driven input at every stage of development, the N.E.K.O. offers players an arcade controller that delivers a competitive advantage.
Design Architecture & Advanced Ergonomics
In close consultation and collaboration with FGC professional and casual gamers in Japan, the N.E.K.O. was designed to deliver superior comfort and performance through an ergonomically positioned faceplate, additional and optimally placed programmable inputs, precisely calibrated weight and dimensions, an enhanced non-slip base, and precision-engineered buttons that allow for smooth transitions from button to button—ensuring combos hit effortlessly every time.
Dual Firmware — Competition Ready
The N.E.K.O. can be easily configured with standard or competition-ready firmware. Standard firmware is meant for casual players and enables turbo, macro programming, and command remapping. Competition ready firmware has been configured to ensure easy compliance with international FGC competition standards.
Customization
Switches, art, and inputs are customizable on the N.E.K.O. Get the right feel and extend device longevity with swappable low-profile Kailh mechanical switches. Easily customize panel artwork for a personalized aesthetic. Reassign commands to optimally positioned programmable buttons or assign up to 16 commands in custom macros for an elevated gaming experience. Three SOCD modes allow for additional customization and flexibility.
The N.E.K.O. is compatible with PC, PS4, and Switch. For further information regarding pricing and regional availability, please reach out to Mad Catz at the contacts below.
The N.E.K.O. is scheduled to be exhibited and will be available for sale at the Mad Catz booth at EVO Japan 2025, which is being held at Tokyo Big Sight from Friday, May 9th.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Samsung Bioepis Enters into a Strategic Partnership with NIPRO for Commercialization of Multiple Biosimilars in Japan
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. ('Samsung Bioepis') announced today that the company has entered into a license, development and commercialization agreement with NIPRO Corporation ('NIPRO') for multiple biosimilar candidates including SB17, ustekinumab biosimilar candidate, in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan." Share Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for commercialization of the medicines in Japan. 'This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,' said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. 'We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.' About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: and follow us on social media – LinkedIn, X.
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
2 hours ago
- Yahoo
SQUARE ENIX Brings FINAL FANTASY XVI and FINAL FANTASY VII REMAKE to Xbox
FINAL FANTASY XVI Game and Free Demo Now Available on Xbox with Xbox Play Anywhere Support LOS ANGELES, June 08, 2025--(BUSINESS WIRE)--As part of SQUARE ENIX's multi-platform strategy and aim to deliver more games to Xbox fans, today the company announced that FINAL FANTASY™ XVI is available digitally for Xbox Series X|S and Xbox PC with Xbox Play Anywhere support starting today, and FINAL FANTASY VII REMAKE INTERGRADE will be arriving digitally to the Xbox Series X|S and Xbox PC with Xbox Play Anywhere support this Winter. With this announcement during the Xbox Games Showcase, every mainline, single-player FINAL FANTASY game, as well as the critically-acclaimed MMORPG FINAL FANTASY XIV Online, is now available on Xbox Series X|S and Xbox PC. Check out the announcement trailers at:FINAL FANTASY XVI - FINAL FANTASY VII REMAKE INTERGRADE - FINAL FANTASY XVI, the latest mainline numbered title in the FINAL FANTASY series, launches digitally today on Xbox Series X|S and Xbox PC as the full FINAL FANTASY XVI Complete Edition, which includes the exciting DLC chapters "Echoes of the Fallen" and "The Rising Tide" at a discounted price, or individually as the standalone base game, DLC chapters, and FINAL FANTASY XVI Expansion Pass. FINAL FANTASY XVI also supports Xbox Play Anywhere, allowing full cross-entitlement and cross-save across console, PC or cloud, and giving players the option of how they want to jump into FINAL FANTASY XVI's frenetic battles and larger than life Eikon clashes as they play as Clive on his quest for revenge. Purchasing either edition will get you the following in-game items: Blood Sword, Braveheart Sword, Brave Blade, Cait Sith's Charm, and the Sixteen Bells Orchestrion. The adrenaline-filled FINAL FANTASY XVI Demo is also currently available free for download for the Xbox Series X|S, with the save data carrying over to the full game. Experience the beginning of Clive's epic tale and learn about his ambitions and goals by downloading the FINAL FANTASY XVI Demo. FINAL FANTASY XVI is rated M (Mature). More information on the base game, "Echoes of the Fallen," "The Rising Tide" and the Expansion Pass is available on the official website at: FINAL FANTASY VII REMAKE INTERGRADE is the expanded edition of the first entry in the FINAL FANTASY VII remake project and includes an additional story arc that takes place during the game's events. In FINAL FANTASY VII REMAKE INTERGRADE, players will be able to relive the first act of the iconic 1997 game as Cloud Strife, the legendary hero, who meets unforgettable allies and explores the dystopian city of Midgar. Culminating in a dramatic escape, this pivotal chapter sets the stage for one of gaming's most legendary stories. With over seven million copies shipped and sold digitally worldwide on the PlayStation and PC platforms, this upcoming release marks the project's debut on an Xbox platform, giving a new audience of players a chance to experience 2020's The Game Awards RPG of the Year* for the first time ever. FINAL FANTASY VII REMAKE INTERGRADE will be available for the Xbox Series X|S and Xbox PC this Winter. For more information, visit: *PS4 Version Related Links FINAL FANTASY XVI:Official Website: X (previously Twitter): @FinalFantasyXVI YouTube: Instagram: @FinalFantasyXVI #FinalFantasy #FF16 FINAL FANTASY VII REMAKE INTERGRADE:Official Website: X (previously Twitter): TikTok: Facebook: Threads: YouTube: Instagram: #FinalFantasy #FF7R About FINAL FANTASY XVI FINAL FANTASY XVI introduces players to an original standalone story in the FINAL FANTASY universe, an epic dark fantasy that takes place in the realm of Valisthea – a land blessed in the light of the Mothercrystals, and where peace falters as the spread of the Blight threatens to destroy their dominions. The fate of the land is decided by the Eikons, mighty summoned beasts and their Dominants, men and women who have been blessed with the ability to call upon and wield them. This is the tale of Clive Rosfield, a warrior granted the title "First Shield of Rosaria" and sworn to protect his younger brother Joshua, the Dominant of the Phoenix, Eikon of Fire. Before long, Clive will be caught up in a great tragedy and swear revenge on the Dark Eikon known as Ifrit, a mysterious entity that brings calamity in its wake. The first DLC chapter, "Echoes of the Fallen," unlocks new story, battles, weapons, accessories, level cap and more. The adventure begins before the base game's final battle, as strange, dark crystals begin to circulate on the black market. Players will follow Clive and company during their investigations as they encounter a group of suspicious traders, leading them to a long-abandoned Fallen tower known as the Sagespire and the terrible secrets that await within. The second, and final DLC chapter, "The Rising Tide," brings an all-new story, battles, sidequests, weapons, accessories, level cap and more, adding a new depth to Clive's journey before the exciting conclusion of FINAL FANTASY XVI. Players will gain new Eikonic abilities, explore a beautiful new area in the hidden land of Mysidia, and dive into battle against the legendary water Eikon, Leviathan the Lost. This DLC also adds brand new end-game content with the Kairos Gate, where players will challenge 20 stages of intense scored and ranked battles against waves of enemies. About FINAL FANTASY VII First released in 1997 on the PlayStation® computer entertainment system, FINAL FANTASY VII celebrated its 25th Anniversary in 2022. The game is universally regarded as a hallmark title of the RPG genre. The original title received high praise for its epic storyline, unique characters, and movie sequences that utilized the most cutting-edge technology of the time. Since then, the game revolving around iconic hero, Cloud Strife and his pursuit of the antagonist Sephiroth has sold over 15.1 million copies worldwide and continues to receive widespread acclaim from critics and fans around the world. The popular game has even expanded into spin-offs, films and merchandise. Now, Square Enix's FINAL FANTASY VII remake project created by a team of original and new developers, retells the story of the genre-redefining RPG across three distinct, and standalone games. The first game of the trilogy, FINAL FANTASY VII REMAKE is now available on the PC and the PS5® and PS4® consoles, will be available this winter for the Xbox Series X|S, Xbox PC, and Nintendo Switch™ 2 platforms. FINAL FANTASY VII REBIRTH, the second game in the trilogy, has been praised by both players and critics across the globe, earning more than 125 perfect scores from media and 40 Game of the Year awards, and is available now for PC and the PS5® console. About FINAL FANTASY For over 35 years, the FINAL FANTASY series has delighted generations of gamers and millions of players worldwide through beloved role-playing adventures that are built upon the benchmarks of spectacular visuals, highly imaginative worlds, rich stories, memorable characters, and technical and gameplay innovation leading the industry and earning the highest accolades from around the world. Each mainline game in the series is a completely new experience, and an ideal entry-point to the series. Titles of the series have sold over 200 million units worldwide. About Square Enix, Inc. Square Enix, Inc. develops, publishes, distributes and licenses SQUARE ENIX® and TAITO® branded entertainment content throughout the Americas as part of the Square Enix group of companies. The Square Enix group of companies boasts a valuable portfolio of intellectual property including: FINAL FANTASY™, which has sold over 200 million units worldwide; DRAGON QUEST®, which has sold over 94 million units worldwide; and the legendary SPACE INVADERS®. Square Enix, Inc. is a U.S.-based, wholly owned subsidiary of Square Enix Holdings Co., Ltd. More information on Square Enix, Inc. can be found at FINAL FANTASY XVI © SQUARE ENIXFINAL FANTASY VII REMAKE © SQUARE ENIXLOGO ILLUSTRATION:© YOSHITAKA AMANOCHARACTER DESIGN: TETSUYA NOMURA / ROBERTO FERRARIXbox Series X|S, the Games for Windows logo and Xbox logos are registered trademarks or trademarks of the Microsoft group of companies and are used under license. All other trademarks are properties of their respective owners. View source version on Contacts Stephanie Changus-pr@ Sign in to access your portfolio
